Why the study?
Does tirzepatide or liraglutide improve cardiac function and survival in an angiotensin II-induced heart failure mouse model?
Does tirzepatide or liraglutide improve cardiac function and survival in an angiotensin II-induced heart failure mouse model?
Tirzepatide and liraglutide preserve cardiac function in a mouse model of heart failure, with tirzepatide additionally improving survival, suggesting potential utility in HFrEF.
Answers are grounded in this paper and cite their sources.
Should not change HFrEF practice; hypothesis-generating for tirzepatide in angiotensin II-induced failure.
Lira and TZP preserved cardiac function and decreased markers of hypertrophy and fibrosis in mice with AngII-induced heart failure, whereas TZP also significantly decreased mortality. In addition to HFpEF, the use of incretin analogues may also be of clinical relevance in the treatment of HFrEF. However, as patients with heart failure, AngII level is elevated and can cause weight loss/cachexia, the usage of incretin analogues to treat non-obese heart failure patients should be considered.
No takes yet. Share an insight, caveat, or question.
Hegedűs et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: